JP2021519072A5 - - Google Patents
Info
- Publication number
- JP2021519072A5 JP2021519072A5 JP2020551549A JP2020551549A JP2021519072A5 JP 2021519072 A5 JP2021519072 A5 JP 2021519072A5 JP 2020551549 A JP2020551549 A JP 2020551549A JP 2020551549 A JP2020551549 A JP 2020551549A JP 2021519072 A5 JP2021519072 A5 JP 2021519072A5
- Authority
- JP
- Japan
- Prior art keywords
- gnc
- cancer cells
- guidance
- binding domain
- navigation control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024180215A JP7781243B2 (ja) | 2018-03-27 | 2024-10-15 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862648880P | 2018-03-27 | 2018-03-27 | |
| US201862648888P | 2018-03-27 | 2018-03-27 | |
| US62/648,880 | 2018-03-27 | ||
| US62/648,888 | 2018-03-27 | ||
| PCT/US2019/024105 WO2019191120A1 (en) | 2018-03-27 | 2019-03-26 | Guidance and navigation control proteins and method of making and using thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024180215A Division JP7781243B2 (ja) | 2018-03-27 | 2024-10-15 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519072A JP2021519072A (ja) | 2021-08-10 |
| JP2021519072A5 true JP2021519072A5 (enExample) | 2022-05-11 |
| JP7573441B2 JP7573441B2 (ja) | 2024-10-25 |
Family
ID=68060498
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551549A Active JP7573441B2 (ja) | 2018-03-27 | 2019-03-26 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
| JP2020551503A Pending JP2021519289A (ja) | 2018-03-27 | 2019-03-26 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
| JP2023216572A Pending JP2024045111A (ja) | 2018-03-27 | 2023-12-22 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
| JP2024180215A Active JP7781243B2 (ja) | 2018-03-27 | 2024-10-15 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551503A Pending JP2021519289A (ja) | 2018-03-27 | 2019-03-26 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
| JP2023216572A Pending JP2024045111A (ja) | 2018-03-27 | 2023-12-22 | ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法 |
| JP2024180215A Active JP7781243B2 (ja) | 2018-03-27 | 2024-10-15 | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US12029761B2 (enExample) |
| EP (2) | EP3774918A4 (enExample) |
| JP (4) | JP7573441B2 (enExample) |
| KR (2) | KR20200139130A (enExample) |
| CN (5) | CN118580363A (enExample) |
| AU (4) | AU2019243448B2 (enExample) |
| CA (2) | CA3094997A1 (enExample) |
| IL (4) | IL312224B2 (enExample) |
| SG (2) | SG11202008474QA (enExample) |
| TW (2) | TW202003037A (enExample) |
| WO (2) | WO2019191120A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11987635B2 (en) * | 2017-06-25 | 2024-05-21 | Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Anti-4-1BB antibodies and methods of making and using thereof |
| US20200157224A1 (en) * | 2017-06-25 | 2020-05-21 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| KR102763369B1 (ko) * | 2017-06-25 | 2025-02-05 | 시스트이뮨, 인코포레이티드 | 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 |
| US20250376531A9 (en) * | 2017-06-25 | 2025-12-11 | Systimmune, Inc. | Anti-4-1bb antibodies and methods of making and using thereof |
| EP3645738A4 (en) * | 2017-06-25 | 2021-08-18 | Systimmune, Inc. | ANTI-PD-L1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF |
| TWI828625B (zh) * | 2017-06-25 | 2024-01-11 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質以及彼之製造及使用方法 |
| SG11202008474QA (en) * | 2018-03-27 | 2020-10-29 | Systimmune Inc | Guidance and navigation control proteins and method of making and using thereof |
| JP7592712B2 (ja) * | 2019-11-06 | 2024-12-02 | システィミューン， インク． | ガイダンス及びナビゲーションコントロールタンパク質、その製造方法及び使用方法 |
| EP4077374A4 (en) * | 2019-12-20 | 2023-12-27 | Kisoji Biotechnology Inc. | POLYPEPTIDES, PROTEIN COMPLEXES AND METHODS FOR PRODUCING THE SAME |
| WO2021178253A1 (en) * | 2020-03-03 | 2021-09-10 | Systimmune, Inc. | Anti-cd19 antibodies and methods of using and making thereof |
| TWI908779B (zh) * | 2020-03-17 | 2025-12-21 | 美商西雅圖免疫公司 | 引導及導航控制(gnc)抗體樣蛋白質及製造與使用其之方法 |
| MX2023003304A (es) * | 2020-09-21 | 2023-05-09 | Systimmune Inc | Complejo de union de egfr y metodo de fabricacion y uso del mismo. |
| AU2022214319A1 (en) | 2021-01-28 | 2023-08-03 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for treating cytokine release syndrome |
| EP4346890A4 (en) * | 2021-05-28 | 2025-07-09 | Xyone Therapeutics Inc | MULTI-SPECIFIC ANTIBODY CONSTRUCTS AGAINST THE MUC1-C/EXTRACELLULAR DOMAIN (MUC1-C/ECD) |
| KR20240099460A (ko) | 2021-11-11 | 2024-06-28 | 리제너론 파아마슈티컬스, 인크. | Cd20-pd1 결합 분자 및 이의 사용 방법 |
| US20250346681A1 (en) * | 2022-04-11 | 2025-11-13 | Astrazeneca Ab | T cell binding proteins |
| EP4507790A1 (en) | 2022-04-11 | 2025-02-19 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| CN120857940A (zh) | 2023-02-17 | 2025-10-28 | 瑞泽恩制药公司 | 对cd3/taa双特异性抗体有反应的诱导型nk细胞 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1354600A1 (en) * | 2002-04-19 | 2003-10-22 | Affimed Therapeutics AG | Antibody combination useful for tumor therapy |
| EP2646468B1 (en) | 2010-12-01 | 2018-07-25 | AlderBio Holdings LLC | Anti-ngf compositions and use thereof |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| EP2930188A1 (en) * | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
| JP6871155B2 (ja) * | 2014-07-25 | 2021-05-12 | メモリアル スローン ケタリング キャンサー センター | 二重特異性ｈｅｒ２及びｃｄ３結合分子 |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| WO2016105450A2 (en) * | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| CA2973720A1 (en) * | 2015-01-14 | 2016-07-21 | Compass Therapeutics Llc | Multispecific immunomodulatory antigen-binding constructs |
| US10526404B2 (en) | 2015-04-29 | 2020-01-07 | Institute For Research In Biomedicine | Multispecific anti GM-CSF antibodies |
| WO2017011342A1 (en) * | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| EP3156417A1 (en) * | 2015-10-13 | 2017-04-19 | Affimed GmbH | Multivalent fv antibodies |
| KR20180096789A (ko) * | 2016-01-11 | 2018-08-29 | 인히브릭스, 인크. | 다가 및 다중특이적 41bb-결합 융합 단백질 |
| CA3020633A1 (en) * | 2016-04-13 | 2017-10-19 | Sanofi | Trispecific and/or trivalent binding proteins |
| KR20180133442A (ko) * | 2016-04-13 | 2018-12-14 | 비비아 바이오테크 에스.엘. | 생체외 bite 활성화된 t 세포 |
| US10188749B2 (en) * | 2016-04-14 | 2019-01-29 | Fred Hutchinson Cancer Research Center | Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers |
| MX2018012472A (es) * | 2016-04-15 | 2019-08-12 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras variantes de ligando icos y sus usos. |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| CN106589129B (zh) * | 2016-12-30 | 2021-03-05 | 上海近岸生物科技有限公司 | 一种结合cd19、cd3和cd28的三功能分子及其应用 |
| US20200157224A1 (en) * | 2017-06-25 | 2020-05-21 | Systimmune, Inc. | Multi-specific antibodies and methods of making and using thereof |
| KR102763369B1 (ko) * | 2017-06-25 | 2025-02-05 | 시스트이뮨, 인코포레이티드 | 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도 |
| TWI828625B (zh) * | 2017-06-25 | 2024-01-11 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質以及彼之製造及使用方法 |
| SG11202008474QA (en) * | 2018-03-27 | 2020-10-29 | Systimmune Inc | Guidance and navigation control proteins and method of making and using thereof |
-
2019
- 2019-03-26 SG SG11202008474QA patent/SG11202008474QA/en unknown
- 2019-03-26 EP EP19776947.4A patent/EP3774918A4/en active Pending
- 2019-03-26 SG SG11202008470WA patent/SG11202008470WA/en unknown
- 2019-03-26 KR KR1020207019089A patent/KR20200139130A/ko active Pending
- 2019-03-26 KR KR1020207019088A patent/KR20200135935A/ko active Pending
- 2019-03-26 AU AU2019243448A patent/AU2019243448B2/en active Active
- 2019-03-26 CA CA3094997A patent/CA3094997A1/en active Pending
- 2019-03-26 CN CN202410657080.1A patent/CN118580363A/zh active Pending
- 2019-03-26 CN CN201980006977.5A patent/CN111527108A/zh active Pending
- 2019-03-26 CN CN202311257825.7A patent/CN117285642A/zh active Pending
- 2019-03-26 AU AU2019243453A patent/AU2019243453B2/en active Active
- 2019-03-26 CN CN202311257564.9A patent/CN117285641A/zh active Pending
- 2019-03-26 EP EP19775882.4A patent/EP3773621A4/en active Pending
- 2019-03-26 JP JP2020551549A patent/JP7573441B2/ja active Active
- 2019-03-26 WO PCT/US2019/024105 patent/WO2019191120A1/en not_active Ceased
- 2019-03-26 IL IL312224A patent/IL312224B2/en unknown
- 2019-03-26 JP JP2020551503A patent/JP2021519289A/ja active Pending
- 2019-03-26 US US17/040,513 patent/US12029761B2/en active Active
- 2019-03-26 IL IL319102A patent/IL319102A/en unknown
- 2019-03-26 US US17/040,519 patent/US20210008113A1/en active Pending
- 2019-03-26 CA CA3094996A patent/CA3094996A1/en active Pending
- 2019-03-26 WO PCT/US2019/024111 patent/WO2019191125A1/en not_active Ceased
- 2019-03-26 IL IL271325A patent/IL271325B2/en unknown
- 2019-03-26 IL IL271348A patent/IL271348B2/en unknown
- 2019-03-26 CN CN201980006846.7A patent/CN111566127B/zh active Active
- 2019-03-27 TW TW108110660A patent/TW202003037A/zh unknown
- 2019-03-27 TW TW108110699A patent/TW201945013A/zh unknown
-
2023
- 2023-12-22 JP JP2023216572A patent/JP2024045111A/ja active Pending
-
2024
- 2024-08-02 AU AU2024205484A patent/AU2024205484A1/en active Pending
- 2024-08-02 AU AU2024205487A patent/AU2024205487A1/en active Pending
- 2024-10-15 JP JP2024180215A patent/JP7781243B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519072A5 (enExample) | ||
| JP2020529864A5 (enExample) | ||
| JP2022510218A5 (enExample) | ||
| JP2023123502A5 (enExample) | ||
| AU2015303135B2 (en) | SIRP-alpha immunoglobulin fusion proteins | |
| ES2850325T3 (es) | Anticuerpos biespecíficos contra CD3epsilon y ROR1 | |
| JP2022516557A5 (enExample) | ||
| JP2020530777A5 (enExample) | ||
| JP2018525033A5 (enExample) | ||
| JP2024023228A5 (enExample) | ||
| TWI874613B (zh) | 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法 | |
| Urbanska et al. | Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells | |
| JP2022551081A5 (enExample) | ||
| JP2023502108A5 (enExample) | ||
| CN115698088A (zh) | 免疫细胞衔接器多特异性结合蛋白及其制备和应用 | |
| CN115066274A (zh) | 三价结合分子 | |
| EP4355781A1 (en) | Anti-cd307e single-domain antibodies, uses thereof in car t-cell and for the treatment of diseases | |
| JP2024508672A5 (enExample) | ||
| AU2017359813A1 (en) | Anti-PD-1/anti-HER2 natural antibody structure-like bispecific antibody of heterodimeric form and preparation thereof | |
| JP2020535796A5 (enExample) | ||
| CN111699201A (zh) | 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法 | |
| JP2023546725A5 (enExample) | ||
| JP2022513372A5 (enExample) | ||
| WO2022148410A1 (zh) | 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| JP2024504162A5 (enExample) |